TIGIT checkpoint inhibition for myeloma

In this issue of Blood, 2 companion papers by Guillerey et al' and Minnie et ale investigate mechanisms underlying immune effector dysfunction in myeloma and highlight T -cell immunoglobulin and ITIM domains (TIGIT) blockade as a novel checkpoint inhibition strategy.